LONDON and WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) — GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion). The proposed transaction …
Tag Archives: Tesaro
December, 2018
October, 2017
-
27 October
Evotec and Tesaro Partner to Discover Novel Immuno-Oncology Agents
HAMBURG, Germany–(BUSINESS WIRE)–Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and TESARO, Inc. (“TESARO”) today announced a three-year integrated drug discovery collaboration to discover and develop novel small molecule product candidates against an undisclosed immuno-oncology (IO) target. Under the terms of the collaboration, Evotec will apply its integrated drug …
March, 2017
-
28 March
Tesaro’s PARP Inhibitor Zejula Wins FDA Approval for Treatment of Ovarian Cancer
WALTHAM, MA, March 27, 2017 – TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ZEJULA™ (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor, for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary …
January, 2017
-
13 January
FDA Denies Approval of Tesaro’s NDA for its Rolapitant IV
WALTHAM, Mass., Jan. 11, 2017 (GLOBE NEWSWIRE) — TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the rolapitant IV New Drug Application (NDA) for the prevention of delayed nausea and vomiting associated with …
December, 2016
-
20 December
Tesaro Announces Priority Review Designation for Niraparib NDA
WALTHAM, Mass., Dec. 20, 2016 (GLOBE NEWSWIRE) — TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the niraparib New Drug Application (NDA). Niraparib is a PARP inhibitor that is being evaluated as a potential new treatment …
September, 2016
-
14 September
Tesaro’s Niraparib Receives Fast Track Designation from the FDA
WALTHAM, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) — TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to niraparib for the treatment of patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. TESARO has initiated …
June, 2016
-
29 June
Tesaro’s PARP Inhibitor Meets Primary Endpoint in Late-Stage Ovarian Cancer Trial
WALTHAM, Mass., June 29, 2016 (GLOBE NEWSWIRE) — TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Phase 3 NOVA trial of niraparib successfully achieved its primary endpoint of progression-free survival (PFS). This trial demonstrated that niraparib significantly prolonged PFS compared to control among patients who are germline …
April, 2016
-
6 April
Janssen to Pay $85 Million for Licensing Rights to Tesaro’s Prostate Cancer Drug
WALTHAM, Mass., April 06, 2016 (GLOBE NEWSWIRE) — TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, and Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced a global collaboration and license agreement focused on the development and commercialization of niraparib specifically for the treatment of …
March, 2016
-
30 March
Tesaro and MD Anderson Enter Immuno-Oncology Collaboration
WALTHAM, Mass. and HOUSTON, March 29, 2016 (GLOBE NEWSWIRE) — TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, and the Institute for Applied Cancer Science at The University of Texas MD Anderson Cancer Center today announced an exclusive collaboration to discover and develop small molecule product candidates against undisclosed immuno-oncology targets. …
February, 2016
-
22 February
Myriad Expands Diagnostic Research Collaboration with TESARO and Merck
SALT LAKE CITY, Feb. 22, 2016 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced a strategic research collaboration with TESARO and Merck, known as MSD outside the U.S. and Canada, to help identify potential responders to an investigational combination drug therapy …